It's extremely encouraging to see people mis-stating things, like claiming that the "de-risking" that many of us have written about is based on Kevetrin, when in fact it is based on the superb results Brilacidin has had (Brilacidin results alone would make the company worth the current share price); and fretting about the company's ability to fund trials, when it has been explained MANY times here that the company has "insurance" by having a funder (Aspire) which is eager to give it more funding even if for whatever reason the CEO decides against a partnership deal; and "worries" about valuation, when a company that has clinical trials going for 3 different drugs, in 3 completely different areas of medicine, is going for a paltry 3.50/share. (Look at the value that was put on Cubicin, which for many reasons, all of which have been discussed here at length, was ridiculously overpriced in the buy-out), etc. etc. etc.
Very heartening to see people saying they are so very very worried. I guess I'd be worried too, if I didn't read the board, didn't understand what was posted, or was short, or wanted to buy more stock cheap. But since I do know what I have invested in, I am not worried. This is a stock that HAS been "de-risked" by the acquisition of defensin-mimetic intellectual property. And if somehow the stock is whacked down once again by whatever means (like those multiple 100 share lot "sales" that we've seen when the stock was walked down in the past) , I guess I'll just sell some of my other stocks and buy more, giving thanks to the silly people who were willing to sell to me.
By the way, the characterization of Kevetrin as a "chemo agent" is completely wrong. It is NOT chemotherapy. The most basic reading of the description of what it seeks to do would indicate that to any casual reader. One does not need an M.D. degree to understand the difference.
